| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695259 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
Use of adjuvant GD chemotherapy for Stage I uterine leiomyosarcoma has increased significantly in the last decade, despite unclear benefit. Compared to no chemotherapy, 4-6Â cycles of adjuvant GD chemotherapy does not appear to alter survival outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Ramey D. Littell, Lue-Yen Tucker, Tina Raine-Bennett, Ted E. Palen, Eve Zaritsky, Romain Neugebauer, Julia Embry-Schubert, Scott E. Lentz,